List of Tables
Table 1. Global Cancer Angiogenesis Inhibitors Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Cancer Angiogenesis Inhibitors Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Cancer Angiogenesis Inhibitors Market Competitive Situation by Manufacturers in 2024
Table 4. Global Cancer Angiogenesis Inhibitors Sales (K Pcs) of Key Manufacturers (2020-2025)
Table 5. Global Cancer Angiogenesis Inhibitors Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Cancer Angiogenesis Inhibitors Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Cancer Angiogenesis Inhibitors Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Cancer Angiogenesis Inhibitors Average Price (USD/Pcs) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Cancer Angiogenesis Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Cancer Angiogenesis Inhibitors, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Cancer Angiogenesis Inhibitors, Product Type & Application
Table 12. Global Key Manufacturers of Cancer Angiogenesis Inhibitors, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Cancer Angiogenesis Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Angiogenesis Inhibitors as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Cancer Angiogenesis Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Cancer Angiogenesis Inhibitors Sales by Region (2020-2025) & (K Pcs)
Table 18. Global Cancer Angiogenesis Inhibitors Sales Market Share by Region (2020-2025)
Table 19. Global Cancer Angiogenesis Inhibitors Sales by Region (2026-2031) & (K Pcs)
Table 20. Global Cancer Angiogenesis Inhibitors Sales Market Share by Region (2026-2031)
Table 21. Global Cancer Angiogenesis Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Region (2020-2025)
Table 23. Global Cancer Angiogenesis Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Region (2026-2031)
Table 25. North America Cancer Angiogenesis Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Cancer Angiogenesis Inhibitors Sales by Country (2020-2025) & (K Pcs)
Table 27. North America Cancer Angiogenesis Inhibitors Sales by Country (2026-2031) & (K Pcs)
Table 28. North America Cancer Angiogenesis Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Cancer Angiogenesis Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Cancer Angiogenesis Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Cancer Angiogenesis Inhibitors Sales by Country (2020-2025) & (K Pcs)
Table 32. Europe Cancer Angiogenesis Inhibitors Sales by Country (2026-2031) & (K Pcs)
Table 33. Europe Cancer Angiogenesis Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Cancer Angiogenesis Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Cancer Angiogenesis Inhibitors Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Cancer Angiogenesis Inhibitors Sales by Region (2020-2025) & (K Pcs)
Table 37. Asia Pacific Cancer Angiogenesis Inhibitors Sales by Region (2026-2031) & (K Pcs)
Table 38. Asia Pacific Cancer Angiogenesis Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Cancer Angiogenesis Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Cancer Angiogenesis Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Cancer Angiogenesis Inhibitors Sales by Country (2020-2025) & (K Pcs)
Table 42. Latin America Cancer Angiogenesis Inhibitors Sales by Country (2026-2031) & (K Pcs)
Table 43. Latin America Cancer Angiogenesis Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Cancer Angiogenesis Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Cancer Angiogenesis Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Cancer Angiogenesis Inhibitors Sales by Country (2020-2025) & (K Pcs)
Table 47. Middle East and Africa Cancer Angiogenesis Inhibitors Sales by Country (2026-2031) & (K Pcs)
Table 48. Middle East and Africa Cancer Angiogenesis Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Cancer Angiogenesis Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Cancer Angiogenesis Inhibitors Sales (K Pcs) by Type (2020-2025)
Table 51. Global Cancer Angiogenesis Inhibitors Sales (K Pcs) by Type (2026-2031)
Table 52. Global Cancer Angiogenesis Inhibitors Sales Market Share by Type (2020-2025)
Table 53. Global Cancer Angiogenesis Inhibitors Sales Market Share by Type (2026-2031)
Table 54. Global Cancer Angiogenesis Inhibitors Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Cancer Angiogenesis Inhibitors Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Type (2020-2025)
Table 57. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Type (2026-2031)
Table 58. Global Cancer Angiogenesis Inhibitors Price (USD/Pcs) by Type (2020-2025)
Table 59. Global Cancer Angiogenesis Inhibitors Price (USD/Pcs) by Type (2026-2031)
Table 60. Global Cancer Angiogenesis Inhibitors Sales (K Pcs) by Application (2020-2025)
Table 61. Global Cancer Angiogenesis Inhibitors Sales (K Pcs) by Application (2026-2031)
Table 62. Global Cancer Angiogenesis Inhibitors Sales Market Share by Application (2020-2025)
Table 63. Global Cancer Angiogenesis Inhibitors Sales Market Share by Application (2026-2031)
Table 64. Global Cancer Angiogenesis Inhibitors Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Cancer Angiogenesis Inhibitors Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Application (2020-2025)
Table 67. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Application (2026-2031)
Table 68. Global Cancer Angiogenesis Inhibitors Price (USD/Pcs) by Application (2020-2025)
Table 69. Global Cancer Angiogenesis Inhibitors Price (USD/Pcs) by Application (2026-2031)
Table 70. Intas Pharmaceuticals Company Information
Table 71. Intas Pharmaceuticals Description and Business Overview
Table 72. Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 73. Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Product
Table 74. Intas Pharmaceuticals Recent Developments/Updates
Table 75. Kyowa Hakko Kirin Company Information
Table 76. Kyowa Hakko Kirin Description and Business Overview
Table 77. Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 78. Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Product
Table 79. Kyowa Hakko Kirin Recent Developments/Updates
Table 80. Levolta Pharmaceuticals Company Information
Table 81. Levolta Pharmaceuticals Description and Business Overview
Table 82. Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 83. Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Product
Table 84. Levolta Pharmaceuticals Recent Developments/Updates
Table 85. Mabtech Company Information
Table 86. Mabtech Description and Business Overview
Table 87. Mabtech Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 88. Mabtech Cancer Angiogenesis Inhibitors Product
Table 89. Mabtech Recent Developments/Updates
Table 90. Marsala Biotech Company Information
Table 91. Marsala Biotech Description and Business Overview
Table 92. Marsala Biotech Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 93. Marsala Biotech Cancer Angiogenesis Inhibitors Product
Table 94. Marsala Biotech Recent Developments/Updates
Table 95. Neumedicines Company Information
Table 96. Neumedicines Description and Business Overview
Table 97. Neumedicines Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 98. Neumedicines Cancer Angiogenesis Inhibitors Product
Table 99. Neumedicines Recent Developments/Updates
Table 100. Genentech Company Information
Table 101. Genentech Description and Business Overview
Table 102. Genentech Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 103. Genentech Cancer Angiogenesis Inhibitors Product
Table 104. Genentech Recent Developments/Updates
Table 105. Five Prime Therapeutics Company Information
Table 106. Five Prime Therapeutics Description and Business Overview
Table 107. Five Prime Therapeutics Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 108. Five Prime Therapeutics Cancer Angiogenesis Inhibitors Product
Table 109. Five Prime Therapeutics Recent Developments/Updates
Table 110. Fuji Film Kyowa Kirin Biologics Company Information
Table 111. Fuji Film Kyowa Kirin Biologics Description and Business Overview
Table 112. Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 113. Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Product
Table 114. Fuji Film Kyowa Kirin Biologics Recent Developments/Updates
Table 115. Genexine Company Information
Table 116. Genexine Description and Business Overview
Table 117. Genexine Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 118. Genexine Cancer Angiogenesis Inhibitors Product
Table 119. Genexine Recent Developments/Updates
Table 120. Hetero Drugs Company Information
Table 121. Hetero Drugs Description and Business Overview
Table 122. Hetero Drugs Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 123. Hetero Drugs Cancer Angiogenesis Inhibitors Product
Table 124. Hetero Drugs Recent Developments/Updates
Table 125. ImClone Systems Company Information
Table 126. ImClone Systems Description and Business Overview
Table 127. ImClone Systems Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 128. ImClone Systems Cancer Angiogenesis Inhibitors Product
Table 129. ImClone Systems Recent Developments/Updates
Table 130. Novartis Company Information
Table 131. Novartis Description and Business Overview
Table 132. Novartis Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 133. Novartis Cancer Angiogenesis Inhibitors Product
Table 134. Novartis Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Cancer Angiogenesis Inhibitors Distributors List
Table 138. Cancer Angiogenesis Inhibitors Customers List
Table 139. Cancer Angiogenesis Inhibitors Market Trends
Table 140. Cancer Angiogenesis Inhibitors Market Drivers
Table 141. Cancer Angiogenesis Inhibitors Market Challenges
Table 142. Cancer Angiogenesis Inhibitors Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Cancer Angiogenesis Inhibitors
Figure 2. Global Cancer Angiogenesis Inhibitors Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Cancer Angiogenesis Inhibitors Market Share by Type: 2024 & 2031
Figure 4. VEGF Targeted Therapy Product Picture
Figure 5. FGF Targeted Therapies Product Picture
Figure 6. Oncogene Targeted Therapy Product Picture
Figure 7. Matrix Degrading & Remodeling Targeted Therapy Product Picture
Figure 8. Others Product Picture
Figure 9. Global Cancer Angiogenesis Inhibitors Market Value by Application (2020-2031) & (US$ Million)
Figure 10. Global Cancer Angiogenesis Inhibitors Market Share by Application: 2024 & 2031
Figure 11. Cancer
Figure 12. Interferon Alpha-2α
Figure 13. Ocular Neovascularization
Figure 14. Global Cancer Angiogenesis Inhibitors Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Cancer Angiogenesis Inhibitors Market Size (2020-2031) & (US$ Million)
Figure 16. Global Cancer Angiogenesis Inhibitors Sales (2020-2031) & (K Pcs)
Figure 17. Global Cancer Angiogenesis Inhibitors Average Price (USD/Pcs) & (2020-2031)
Figure 18. Cancer Angiogenesis Inhibitors Report Years Considered
Figure 19. Cancer Angiogenesis Inhibitors Sales Share by Manufacturers in 2024
Figure 20. Global Cancer Angiogenesis Inhibitors Revenue Share by Manufacturers in 2024
Figure 21. Global 5 and 10 Largest Cancer Angiogenesis Inhibitors Players: Market Share by Revenue in Cancer Angiogenesis Inhibitors in 2024
Figure 22. Cancer Angiogenesis Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. Global Cancer Angiogenesis Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 24. North America Cancer Angiogenesis Inhibitors Sales Market Share by Country (2020-2031)
Figure 25. North America Cancer Angiogenesis Inhibitors Revenue Market Share by Country (2020-2031)
Figure 26. U.S. Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Canada Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Europe Cancer Angiogenesis Inhibitors Sales Market Share by Country (2020-2031)
Figure 29. Europe Cancer Angiogenesis Inhibitors Revenue Market Share by Country (2020-2031)
Figure 30. Germany Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. France Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. U.K. Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Italy Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Russia Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Asia Pacific Cancer Angiogenesis Inhibitors Sales Market Share by Region (2020-2031)
Figure 36. Asia Pacific Cancer Angiogenesis Inhibitors Revenue Market Share by Region (2020-2031)
Figure 37. China Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Japan Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. South Korea Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. India Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Australia Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Taiwan Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Indonesia Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Thailand Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Malaysia Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Philippines Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Latin America Cancer Angiogenesis Inhibitors Sales Market Share by Country (2020-2031)
Figure 48. Latin America Cancer Angiogenesis Inhibitors Revenue Market Share by Country (2020-2031)
Figure 49. Mexico Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Brazil Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Argentina Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Middle East and Africa Cancer Angiogenesis Inhibitors Sales Market Share by Country (2020-2031)
Figure 53. Middle East and Africa Cancer Angiogenesis Inhibitors Revenue Market Share by Country (2020-2031)
Figure 54. Turkey Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Saudi Arabia Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. UAE Cancer Angiogenesis Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. Global Sales Market Share of Cancer Angiogenesis Inhibitors by Type (2020-2031)
Figure 58. Global Revenue Market Share of Cancer Angiogenesis Inhibitors by Type (2020-2031)
Figure 59. Global Cancer Angiogenesis Inhibitors Price (USD/Pcs) by Type (2020-2031)
Figure 60. Global Sales Market Share of Cancer Angiogenesis Inhibitors by Application (2020-2031)
Figure 61. Global Revenue Market Share of Cancer Angiogenesis Inhibitors by Application (2020-2031)
Figure 62. Global Cancer Angiogenesis Inhibitors Price (USD/Pcs) by Application (2020-2031)
Figure 63. Cancer Angiogenesis Inhibitors Value Chain
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
